Publication details
Intestinal sulfate-reducing bacteria under the effect of salicylamides derivatives
| Authors | |
|---|---|
| Year of publication | 2016 |
| Type | Article in Proceedings |
| Conference | Achievements and prospects of microbiology |
| MU Faculty or unit | |
| Citation | |
| Field | Microbiology, virology |
| Keywords | salicylamides; bowel diseases; ulcerative colitis; sulfate-reducing bacteria |
| Description | Sulfate-reducing bacteria (SRB) are most likely involved in both the initiation and maintenance of the inflammatory bowel disease (IBD), unfortunately present antibacterial chemotherapeutics used in the treatment of IBD have been ineffective. Thus, the antimicrobial activity of salicylamide derivatives on two different genera of intestinal SRB, Desulfovibrio and Desulfomicrobium was investigated. Six 2-(phenylcarbamoyl)phenyl N-[(benzyloxy)carbonyl]alkanoatesand three 2-hydroxy-N-[(2S)-1-oxo-1-(phenylamino)alkan-2-yl]benzamides showed MIC values in the range from 0.22 to 0.35 microM against Desulfovibrio piger Vib-7 and in the range from 0.27 to 8.52 microM against Desulfomicrobium sp. Rod-9, which is by two orders of magnitude lower compared with ciprofloxacin. |